Patent: 6,462,017
✉ Email this page to a colleague
Summary for Patent: 6,462,017
Title: | Method of reducing side effects of chemotherapy in cancer patients |
Abstract: | A method for reducing the severity of chemotherapy side effects in cancer patients by administering thymosin .alpha..sub.1 in conjunction with the administration of a chemotherapy agent to the patient. As a result of the reduction of post-chemotherapy side effects, patients experience an increase in the quality of life. |
Inventor(s): | Rudolph; Alfred R. (Los Altos Hills, CA), Tam; Vincent Chung-Ying (Hong Kong, HK), Quan; Maggie Jie (Shanghai, CN) |
Assignee: | SciClone Pharmaceuticals, Inc. (San Mateo, CA) |
Application Number: | 09/561,917 |
Patent Claims: | see list of patent claims |
Details for Patent 6,462,017
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Recordati Rare Diseases, Inc. | ELSPAR | asparaginase | For Injection | 101063 | 01/10/1978 | ⤷ Try a Trial | 2039-02-26 |
Merck Teknika Llc | TICE BCG | bcg live | For Injection | 102821 | 06/21/1989 | ⤷ Try a Trial | 2039-02-26 |
Merck Sharp & Dohme Corp. | INTRON A | interferon alfa-2b | For Injection | 103132 | 06/04/1986 | ⤷ Try a Trial | 2039-02-26 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |